Behfar Ehdaie, MD, MPH presented “High Intensity Focused Ultrasound Ablation Outcomes – TR, In Bore” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.
How to cite: Ehdaie, Behfar “High Intensity Focused Ultrasound Ablation Outcomes – TR, In Bore” November, 2023. Accessed Dec 2024. https://grandroundsinurology.com/high-intensity-focused-ultrasound-ablation-outcomes-tr-in-bore/
High Intensity Focused Ultrasound Ablation Outcomes – TR, In Bore – Summary
Behfar Ehdaie, MD, MPH, discusses High-Intensity Focused Ultrasound (HIFU) ablation, particularly focusing on its application in treating prostate cancer. The presentation highlights the recent advancements and clinical outcomes associated with both transrectal (TR) and in-bore HIFU procedures.
Dr. Ehdaie emphasizes the precision and minimal invasiveness of HIFU and outlines the selection criteria for patients. He also discusses the integration of real-time imaging with magnetic resonance imaging (MRI) in in-bore HIFU.
Dr. Ehdaie highlights the promising results demonstrated in clinical outcomes of HIFU ablation, making HIFU an attractive option for eligible patients. He also addresses the ongoing challenges and future directions in HIFU research. The potential for combining HIFU with other therapeutic modalities, such as immunotherapy and targeted therapies, is a promising avenue for enhancing treatment efficacy.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Behfar Ehdaie, MD, MPH, is a urologic surgeon at Memorial Sloan Kettering Cancer Center in New York City. He earned his medical degree at Georgetown University School of Medicine and then went on to a urology residency at the University of Virginia School of Medicine and a fellowship at Memorial Sloan Kettering Cancer Center. Dr. Ehdaie is an expert in minimally invasive surgical techniques for the treatment of urologic cancers, and has a particular interest in novel management of prostate cancer, kidney tumors, and bladder cancer. He has performed more than 500 MRI-guided prostate biopsies and is experienced in doing extensive lymph node removals at the time of prostate surgery. His research is focused on achieving prostate cancer cures while also preserving quality of life, and he is currently the principal investigator on a clinical trial of partial gland ablation that theoretically could allow patients with prostate cancer to receive effective treatment minus side effects like incontinence and erectile dysfunction. Dr. Ehdaie also aims to improve active surveillance by developing a large surveillance clinic that will use advanced imaging and biomarkers to detect cancer progression. Dr. Ehdaie has given presentations on prostate cancer throughout the United States and around the world, and has also published numerous articles and studies in peer-reviewed journals.
